1. A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas. (August 2016) Authors: Fiedler, W.; DeDosso, S.; Cresta, S.; Weidmann, J.; Tessari, A.; Salzberg, M.; Dietrich, B.; Baumeister, H.; Goletz, S.; Gianni, L.; Sessa, C. Journal: European journal of cancer Issue: Volume 63(2016) Page Start: 55 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968). (3rd June 2015) Authors: Joerger, M.; Hess, D.; Delmonte, A.; Gallerani, E.; Fasolo, A.; Gianni, L.; Cresta, S.; Barbieri, P.; Pace, S.; Sessa, C. Journal: British journal of clinical pharmacology Issue: Volume 80:Number 1(2015:Jul.) Page Start: 128 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗